Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $19.0 million.

  • Ultragenyx Pharmaceutical's Other Accumulated Expenses fell 3559.34% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 3559.34%. This contributed to the annual value of $19.0 million for FY2024, which is 3900.3% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Other Accumulated Expenses of $19.0 million as of Q3 2025, which was down 3559.34% from $20.9 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other Accumulated Expenses peaked at $59.9 million during Q3 2022, and registered a low of $19.0 million during Q3 2025.
  • For the 5-year period, Ultragenyx Pharmaceutical's Other Accumulated Expenses averaged around $37.2 million, with its median value being $32.2 million (2021).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Other Accumulated Expenses soared by 10285.94% in 2022 and then tumbled by 5907.52% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Other Accumulated Expenses stood at $42.1 million in 2021, then grew by 23.99% to $52.2 million in 2022, then crashed by 40.22% to $31.2 million in 2023, then plummeted by 39.0% to $19.0 million in 2024, then dropped by 0.4% to $19.0 million in 2025.
  • Its Other Accumulated Expenses was $19.0 million in Q3 2025, compared to $20.9 million in Q2 2025 and $20.6 million in Q1 2025.